"Alopecia Areata" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Loss of scalp and body hair involving microscopically inflammatory patchy areas.
| Descriptor ID |
D000506
|
| MeSH Number(s) |
C17.800.329.937.122.147
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alopecia Areata".
Below are MeSH descriptors whose meaning is more specific than "Alopecia Areata".
This graph shows the total number of publications written about "Alopecia Areata" by people in this website by year, and whether "Alopecia Areata" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2017 | 5 | 0 | 5 |
| 2018 | 9 | 1 | 10 |
| 2019 | 1 | 0 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Alopecia Areata" by people in Profiles.
-
Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis. Dermatitis. 2021 Oct 01; 32(1S):e80-e82.
-
Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol. 2021 10; 85(4):975-976.
-
Black dots in trichoscopy after COVID-19. Can it be telogen effluvium? Dermatol Ther. 2021 Sep; 34(5):e15053.
-
Mild-to-moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective analysis of 32 patients. J Am Acad Dermatol. 2021 09; 85(3):723-725.
-
Race, ethnicity, and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID-19 pandemic. J Am Acad Dermatol. 2021 07; 85(1):209-211.
-
New onset of alopecia areata in a patient with SARS-CoV-2 infection: Possible pathogenetic correlations? J Cosmet Dermatol. 2021 Jul; 20(7):2004-2005.
-
Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib. J Eur Acad Dermatol Venereol. 2021 Jul; 35(7):e411-e412.
-
Telogen effluvium in the new SARS-CoV-2 era. Int J Dermatol. 2021 Jul; 60(7):e265-e266.
-
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther. 2021 03; 34(2):e14746.
-
Immunosuppressive therapies for alopecia areata during COVID-19: A cross-sectional survey study. Dermatol Ther. 2021 03; 34(2):e14762.